Abstract
Interleukin-27 (IL-27) is a pleiotropic cytokine but its immunosuppressive effects predominate during many in vivo immunological challenges. Despite this, evidence from tumor cell line transfer models suggested that IL-27 could promote immune responses in the tumor context. However, the role of IL-27 in immunity against tumors that develop in situ and in tumor immunosurveillance remain undefined. In this study, we demonstrate that tumor development and growth are accelerated in IL-27 receptor α (Il27ra)-deficient mice. Enhanced tumor growth in both carcinogen-induced fibrosarcoma and oncogene-driven mammary carcinoma was associated with decreased interferon-γ production by CD4 and CD8 T cells and increased numbers of regulatory T-cells (Treg). This is the first study to show that IL-27 promotes protective immune responses against endogenous tumors, which is critical as the basis for future development of an IL-27 based therapeutic agent.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
CD8-Positive T-Lymphocytes / immunology*
-
CD8-Positive T-Lymphocytes / pathology
-
Immune Tolerance / genetics
-
Interferon-gamma / genetics
-
Interferon-gamma / immunology
-
Interleukins / genetics
-
Interleukins / immunology*
-
Male
-
Mice
-
Mice, Knockout
-
Neoplasms, Experimental / genetics
-
Neoplasms, Experimental / immunology*
-
Neoplasms, Experimental / pathology
-
Neoplasms, Experimental / therapy
-
Receptors, Cytokine / genetics
-
Receptors, Cytokine / immunology*
-
Receptors, Interleukin
-
Signal Transduction / genetics
-
Signal Transduction / immunology*
-
T-Lymphocytes, Regulatory / immunology*
-
T-Lymphocytes, Regulatory / pathology
Substances
-
Il27 protein, mouse
-
Il27ra protein, mouse
-
Interleukins
-
Receptors, Cytokine
-
Receptors, Interleukin
-
Interferon-gamma
Grants and funding
M.B. is the recipient of a Career Development Fellowship (APP1031277) from the National Health and Medical Research Council (
http://www.nhmrc.gov.au/), Australia. This work was also supported by an Early Career Fellowship (M.B.; 08ECF110) from the Cancer Institute New South Wales (
http://www.cancerinstitute.org.au/). A.S. is the recipient of an Early Career Fellowship from the National Breast Cancer Foundation Australia (
http://www.nbcf.org.au/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.